MAO-B-IN-56 

MAO-B-IN-56 is a multi-target-directed ligand with AChE, BChE, MAO-B, and BACE1 inhibitory activity, with IC₅₀ values of 0.35 μM, 3.22 μM, 0.14 μM, and 3.85 μM respectively, and shows selectivity for AChE over BChE and MAO-B over MAO-A.MAO-B-IN-56 reduces amyloid-beta production, reduces paw edema, improves spatial memory, and enhances Alzheimer's disease hallmarks and associated histopathological alterations.MAO-B-IN-56 can be used for the research of alzheimer's disease^[1].

MAO-B-IN-56 (Compound 3k) shows selectivity for AChE over BChE and MAO-B over MAO-A^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

MAO-B-IN-56 (Compound 3k) (0.028 mmol/kg; single administration) exhibits potent anti-inflammatory activity, reducing carrageenan-induced rat paw edema by 88.88% at 2 h post-induction^[1].
MAO-B-IN-56 (0.026 mmol/kg, administered daily) effectively ameliorates streptozotocin (STZ) (HY-13753)-induced Alzheimer's disease pathology in mice, enhances spatial memory, maintains hippocampal structural integrity, and normalizes key Alzheimer's disease (AD)-related biochemical parameters, but fails to restore recognition memory indicators in the novel object recognition (NOR) test^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

534.59

C₂₆H₂₆N₆O₅S

COC1=CC=C(NC(CN2C=C(/C=N\NC(CNC3=CC=C(S(=O)(N)=O)C=C3)=O)C4=C2C=CC=C4)=O)C=C1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Said MF, et al. In vitro, in vivo, and in silico profiling of optimized hydrazide-hydrazone indole congeners as multi-faceted AChE, BACE1, and MAO-B inhibitors for Alzheimer's disease therapy. Bioorg Chem. 2026;175:109774.